SCHEMBL3379995

SCHEMBL3379995

CS(=O)(=O)Nc1ccc(-c2cccc(Cl)c2)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PGR P06401 3/20 0.51
NR3C1 P04150 2/20 0.51
NR3C2 P08235 2/20 0.51
AR P10275 1/20 0.51
DHODH Q02127 1/20 0.50
MET P08581 1/20 0.49
GAA P10253 1/20 0.49
HPGD P15428 1/20 0.49
MAPK1 P28482 1/20 0.49
KIF11 P52732 2/20 0.49
CYP17A1 P05093 2/20 0.45
BRD4 O60885 3/20 0.44
RORC P51449 1/20 0.43
PTGES2 Q9H7Z7 1/20 0.43
PKM P14618 1/20 0.43
AURKA O14965 1/20 0.43
KDR P35968 1/20 0.43
AURKB Q96GD4 1/20 0.43
TDP2 O95551 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378891 0.86 SLC22A12 (0.52) PGRNR3C1NR3C2METGAA
SCHEMBL3378931 0.83 KIF11 (0.67) METGAAHPGDMAPK1KIF11
SCHEMBL3375688 0.82 KIF11 (0.56) GAAHPGDMAPK1KIF11BRD4
SCHEMBL3377121 0.81 TDP1 (0.51) GAAHPGDMAPK1
SCHEMBL3374747 0.81 KIF11 (0.51) PGRNR3C1NR3C2ARGAA
SCHEMBL3377083 0.81 PTGS2 (0.52) GAAHPGDMAPK1KIF11CYP17A1
SCHEMBL3377794 0.79 DHODH (0.56) DHODHKIF11CYP17A1RORC
SCHEMBL2317675 0.79 PTGS1 (0.57) PGRKIF11PKM
SCHEMBL3376954 0.78 KIF11 (0.48) PGRNR3C1NR3C2ARGAA
SCHEMBL16574001 0.78 BRD4 (0.55) PGRNR3C1NR3C2ARGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 PGR 4327/4885NR3C1 2869/4885NR3C2 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.